Dr Peter Sutherland trained in Australia, the USA and the UK and has since gained over twenty-five years experience in Urological practice. He was the Head of the Urology Department at Adelaide’s largest teaching hospital, The Royal Adelaide for twenty years. With the University of Adelaide’s Department of Surgery, he manages a team of researchers offering trials of new drugs and techniques for many Urological conditions.
Dr Sutherland’s particular areas of interest are prostate cancer, laser treatment of prostatic obstruction, kidney disease and erectile dysfunction.
Robotic surgery
Dr Sutherland was instrumental in leading the first surgical team to introduce robotic radical prostatectomy into the Australian public health system. He has performed more than 2000 da Vinci procedures over an 11 year period making him one of the most experienced robotic surgeons in Australia. He continues to complete more than 130 cases a year and through his association with the Royal Adelaide Hospital, he provides a robotic service to both public and private patients.
Qualifications
- 1976: Graduated University of Adelaide Medical School – MBBS
- 1977: FRACS
- 1982: Fellowship in Urology
- 1982: Fellowship in Urological Surgery
Personal Appointments
1985 – Present: Private practice in Adelaide, South Australia. Principal interests include Andrology and Prostate Disease. The practice has set up Australasia’s first private specialist day surgery managing only urological conditions.
2014: Senior Visiting Consultant in Urology at the Royal Adelaide Hospital, Adelaide.
1995-April 2014: Head of the Urology Unit at the Royal Adelaide Hospital, Adelaide.
1989-1995: Senior Visiting Medical Specialist in Urology at the Royal Adelaide Hospital, Adelaide.
1985-1989: Visiting Medical Specialist in Urology at Flinders Medical Centre, Adelaide under the guidance of Professor Villis Marshall.
1984: Appoiinted: to UCLA Medical Centre as a Foreign Fellow under the guidance of Dr J Kauffmann, Chief of Urology. Again, the main focus of this appointment
was in the area of Andrology.
1983: Appointed to Institute of Urology, London as Clinical Assistant with Dean of the Institute, Mr John Pryor. This Fellowship was principally in the area of Andrology which was Mr Pryor’s main area of interest.
1982: Advanced Trainee (Urology), Flinders Medical Centre under the guidance of Professor Villis Marshall.
1980-1981: Advanced Trainee (Urology), Royal Adelaide Hospital under the guidance of Mr John Maddern, (Head of Unit 1980-1981).
1979: Appointed to Urological Training Post, Royal Adelaide Hospital
1977-1978: Basic Surgical Training, Royal Adelaide Hospital
1976: Internship Royal Adelaide Hospital
Committees
- 1988: President of the Urological Society in South Australia.
- 1987-1992: Appointed to the Australasian Board of Urology.
- 1998-present: Has acted as a National Advisory Board Member for:
- Pfizer and Viagra, Pharmacia and Caverject, Abbott and Uprima, Eli Lilly and Cialis, AMS and their penile prosthetic devices, Bayer-GSK and Levitra, Astra Zeneca, Zoladex and Cosudex, Device Technology and the daVinci Robot, Eli Lilly
- 2004: Principal Surgeon, Robotic Surgical Programme,
Royal Adelaide Hospital. - 2005: Mentor surgeon, Robotic Surgical Programme,
Royal Adelaide Hospital, Australia. - 2006: Mentor surgeon, Robotic Surgical Programme,
St Vincent’s Hospital, Sydney, Australia. - 2007: Mentor surgeon, Robotic Surgical Programme,
St Vincent’s Hospital, Sydney, Australia. - 2007: Mentor surgeon, Robotic Surgical Programme,
Tauronga Hospital, New Zealand. - 2008: Mentor surgeon, Robotic Surgical Programme,
- 2008: John of God Hospital, Perth, Australia.
- 2008: Mentor surgeon, Robotic Surgical Programme,
- 2008: Royal Adelaide Hospital, Australia.
- 2008: Mentor surgeon, Greenslopes Private Hospital.
- 2009: Mentor Surgeon, Greenslopes Private Hospital.
- 2010: Mentor Surgeon, Wesley Hospital, Brisbane
- 2011: Mentor Surgeon, East Kent Hospital, United Kingdom.
- 2011: Mentor Surgeon, Cabrini Hospital, Melbourne.
- 2011: Mentor Surgeon, St Vincent’s Hospital, Sydney.
- 2012: Mentor Surgeon, Macquarie University Hospital,
Hurstville Private Hospital, Sydney. - 2013: Mentor Surgeon, Sydney Adventist Hospital.
- 2014: Mentor Surgeon, St Andrew’s Hospital, Adelaide.
- 2014 – Present: ASERNIP-S advisory clinician
- 2014 – Present: Emerging Technologies and Biostatistics.
Professional Memberships
- South Australian Medical Board
- Royal Australasian College of Surgeons
- Urological Society of Australasia
- Prostate Cancer Foundation of Australia
- Australian Prostate Collaboration
- International Society of Sexual Medicine
- Societe Internationale d’Urologie
- Society of Robotic Surgery – Charter Member
Publications
- Sutherland PD, Matson PL, Masters JR, Pryor JP. Association between infertility
following reversal of vasectomy and the presence of sperm agglutinating activity in
semen. Int J Androl. 1984;7:503-8. - Sutherland PD, Maddern JP, Jose JS, Marshall VR. Urethral stricture after cardiac
surgery.Br J Urol. 1983;55:413-6. - Sutherland PD, Landon GV, Matson PL, Pryor JP. Round headed sperm. Br J
Urol. 1985;57:486. - Sutherland PD, Howard PR, Marshall VR. Colonic infarction following ethanol
embolisation of the kidney. Br J Urol. 1986;58:337. Peter Sutherland - Gallus A, Murphy W, Nacey J, Morris M, Sutherland P, Marshall V, Magnani H.
The influence of Org 10172, and antithrombotic heparinoid, on urinary blood loss
after transurethral prostatectomy. Thromb Res. 1989;56:229-38. - Maddern GJ, Sutherland PD. Laparoscopic exploration for a presumed intraabdominal
testicle.Endosc Surg Allied Technol. 1994; 2:293. - Ricciardelli C, Quinn DI, Raymond WA, McCaul K, Sutherland PD, Stricker PD,
Grygiel JJ, Sutherland RL, Marshall VR, Tilley WD, Horsfall DJ. Elevated levels of
peritumoral chondroitin sulfate are predictive of poor prognosis in patients treated by
radical prostatectomy for early-stage prostate cancer. Cancer Res. 1999 ;59:2324-8. - Tooher R, Sutherland P, Costello A, Gilling P, Rees G, Maddern G. A systematic
review of holmium laser prostatectomy for benign prostatic hyperplasia. J. Urol.
2004;171:1773-81. - McMahon CG, Stuckey BG, Lording DW, Wittert GA, Murphy A, Shin J,
Sutherland PD,Palmer NR, Lowy MP, Jesudason DR, Fredlund P. A 6-month
study of the efficacy and safety of tadalafil in the treatment of erectile dysfunction: a
randomised, double-blind, parallel-group, placebo-controlled study in Australian men.
Int J Clin Pract. 2005;59:143-9. - Borg M, Sutherland P, Stapleton A, Bolt J, Steele D, Landers B, Porter A,
Buxton S, Heilbornn C, Wong HZ. Outcome of post-prostatectomy radiotherapy in
one institution. Australas Radiol. 2006;50:475-80. - Lowy M, Collins S, Bloch M, Gillman M, Lording D, Sutherland P, Wang H,
Stecher V. Quality of erection questionnaire correlates: change in erection quality
with erectile function,hardness, and psychosocial measures in men treated with
sildenafil for erectile dysfunction. J Sex Med. 2007;4:83-92. - Ludbrook G, Sutherland P. Erroneous pulse oximetry readings during robotic
prostatectomy. Anaesth Intensive Care. 2007; 35:144-5. - Porst H, McVary KT, Montorsi F, Sutherland P, Elion-Mboussa A, Wolka AM,
Viktrup L. Effects of once-daily Tadalafil on erectile function in men with erectile
dysfunction and signs and symptoms of benign prostatic hyperplasia. Eur Urol. Eur
Urol. 2009;56:727-35. - Ricciardelli C, Bianco-Miotto T, Jindal S, Dodd TJ, Cohen PA, Marshall VR,
Sutherland PD, Samaratunga H, Kench JG, Dong Y, Wang H, Clements JA,
Risbridger GP, Sutherland RL, Tilley WD, Horsfall DJ; Australian Prostate
Cancer BioResource. Comparative biomarker expression and RNA integrity in
biospecimens derived from radical retropubic and robot-assisted laparoscopic
prostatectomies. Cancer Epidemiol Biomarkers Prev., 2010, 19, 1755-1765. - Centenera, M.; Gillis, J.; Hanson, A.; Jindal, S.; Taylor, R.; Risbridger, G.;
Sutherland, P.; Scher, H.; Raj, G.; Knudsen, K.; Yeadon, T.; Tilley, W.; Butler, L.
Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human
prostate tumors. Clinical Cancer Research, 2012; 18(13):3562-3570 Peter Sutherland - Selth LA; Townley, SL; Bert, AG; Stricker, PD; Sutherland, PD; Horvath, LG;
Goodall, GJ; Butler, LM; Tilley, WD. Circulating microRNAs predict biochemical
recurrence in prostate cancer patients. British Journal of Cancer, 2013; 109(3);641-
650. - Plagakis S, Foreman D, Sutherland P, Fuller A. Transperitoneal robot-assisted
prostatectomy should be considered in prostate cancer patients with pelvic kidneys.
Journal of Endourology Case Reports 2016; 2(1): 38-40 doi: 10.1089/cren.2016.0006 - Plagakis S, Neumann P, OCallaghan M, Foreman D, Fuller A, Sutherland P,
Wells R. Age is not associated with continence outcomes after a robot assisted
laparoscopic radical prostatectomy (RALP) Supportive Care in Cancer 2016; 24 (S1):
S206 - Plagakis S, OCallaghan M, Neumann P, Fuller A, Wells R, Sutherland P,
Foreman D. Age does not affect continence outcome after robot assisted
laparoscopic prostatectomy (RALP). BJU International 2016; 118(S1): 20 - Neumann P, OCallaghan M, Foreman D, Plagakis S, Sutherland P, Fuller A,
Wells R. Bladder neck displacement and continence outcomes within 12 months of
robot assisted radical prostatectomy (RARP). BJU International 2016; 118(S1): 41 - Lin D, Plagakis S, Fuller A, Sutherland P, OCallaghan M, Neumann P, Foreman
D. What affect does prostate volume have on continence after robotic prostatectomy?
ANZ Journal of Continence 2016